A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
iOnctura
Eli Lilly and Company
Northwestern University
Northwestern University
Northwestern University
Shandong Cancer Hospital and Institute
Vanderbilt-Ingram Cancer Center